IL6 and diabetes mellitus: Neither of the two phase 2 trials testing the anti-IL-6 antibodies ziltivekimab and clazakizumab included glycemic traits as endpoints, despite recruiting substantial numbers of patients with diabetes (71% (ref. 9) and 90% (ref. 11), respectively).